Oral Type I Collagen for Relieving Scleroderma

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

May 31, 2005

Conditions
SclerodermaConnective Tissue Diseases
Interventions
DRUG

Oral bovine type I collagen

500 mcg of CI daily for 15 months

DRUG

Placebo

CI placebo daily for 15 months

Trial Locations (12)

10003

Beth Israel Medical Center, New York

20007

Georgetown University Medical Center, Washington D.C.

21224

Johns Hopkins University, Baltimore

29425

Medical University of South Carolina, Charleston

35294

University of Alabama at Birmingham, Birmingham

38163

University of Tennessee Health Science Center, Memphis

48201

Wayne State University, Detroit

77030

The University of Texas Health Science Center at Houston, Houston

90024

University of California Los Angeles, Los Angeles

98101

Virginia Mason Research Center, Seattle

06030-1310

University of Connecticut, Farmington

02188

Boston University School Of Medicine, Boston

All Listed Sponsors
collaborator

Wayne State University

OTHER

collaborator

University of California, Los Angeles

OTHER

collaborator

UTHSC

UNKNOWN

collaborator

Medical University of South Carolina

OTHER

collaborator

Beth Israel Medical Center

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

Georgetown University

OTHER

collaborator

Baltimore VA Medical Center

FED

collaborator

Northwestern University

OTHER

lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT00005675 - Oral Type I Collagen for Relieving Scleroderma | Biotech Hunter | Biotech Hunter